Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;21(9):526-545.
doi: 10.1038/s41584-025-01280-3. Epub 2025 Aug 12.

Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain

Affiliations
Review

Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain

Vicky Batchelor et al. Nat Rev Rheumatol. 2025 Sep.

Abstract

Pain is the primary complaint in individuals with osteoarthritis (OA) and changes as the disease progresses. Anatomical changes in several joint structures potentially contribute to pain, including the increased innervation of the periosteum, synovium and subchondral bone, and the pathological innervation of articular cartilage, which is aneural under physiological conditions. Research has focused on molecules that sensitize afferent neurons, such as neuropeptides, neurotrophins, pro-inflammatory cytokines and ion channels. The neurotrophin nerve growth factor (NGF) is the best validated target in OA pain, with proven analgesic effects in preclinical and clinical studies, although the development of NGF-targeted therapeutics has been hampered by serious side effects. One relatively neglected area of research is the contribution to OA pain of the molecular pathways that mediate remodelling of nerves in disease. Remodelling requires coordination between the nerve and the associated vasculature, along with signals that are received from the surrounding parenchyma. Key cell guidance molecules, including angiogenic factors, ephrins, semaphorins and SLIT proteins are involved in nerve growth during development, and their expression is increased in osteoarthritic joints.

PubMed Disclaimer

Conflict of interest statement

Competing interests: T.L.V. has received research support for STEpUP OA from Biosplice, Fidia, Galapagos, GSK, Novartis, Pfizer and UCB, and has performed ad hoc consultancy for Zoetis 2024. M.Z.C. is Founder and Director of Oxford StemTech Ltd, Human-Cetric DD Ltd, has performed Consultancy and received Honoraria from AbbVie, Brandon Capital, Pfizer, TEVA, has received research support from GSK; and public–private partnership funding for the IM2PACT project. V.B. and T.A.P. declare no competing interests.

References

    1. Safiri, S. et al. Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 79, 819–828 (2020). - PubMed
    1. Hunter, D. J., March, L. & Chew, M. Osteoarthritis in 2020 and beyond: a Lancet commission. Lancet 396, 1711–1712 (2020). - PubMed
    1. O’Neill, T. W. & Felson, D. T. Mechanisms of osteoarthritis (OA) pain. Curr. Osteoporos. Rep. 16, 611–616 (2018). - PubMed - PMC
    1. Felson, D. T. et al. Multiple nonspecific sites of joint pain outside the knees develop in persons with knee pain. Arthritis Rheumatol. 69, 335–342 (2017). - PubMed - PMC
    1. Neogi, T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 21, 1145–1153 (2013). - PubMed - PMC

Substances

LinkOut - more resources